100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
Test Bank For Clayton’s Basic Pharmacology for Nurses 19thEdition By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complete CA$30.76
Add to cart
Quickly navigate to
Preview
  2.  
  3. Clayton’s Basic Pharmacology For Nur
  4.  
  5. Clayton’s Basic Pharmacology for Nur

Exam (elaborations)

Test Bank For Clayton’s Basic Pharmacology for Nurses 19thEdition By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complete
 4 views  0 purchase
  • Course
  • Clayton’s Basic Pharmacology for Nur
  • Institution
  • Clayton’s Basic Pharmacology For Nur

Test Bank For Clayton’s Basic Pharmacology for Nurses 19thEdition By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complete

Preview 4 out of 410  pages

Document information

  • December 5, 2024
  • 410
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers

Subjects

  • test bank for claytons basic pharmacology for nur

Written for

  • Clayton’s Basic Pharmacology for Nur
  • Clayton’s Basic Pharmacology for Nur

Seller

avatar-seller
Verifiedtestbanks

Reviews received

Content preview

Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Edition By
v v v v v v v v v v



Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Complete
v v v v v v v v v

,Chapter 01: Drug Definitions, Standards, and Information Sources Willihnganz:
v v v v v v v v

Clayton’s Basic Pharmacology for Nurses, 19th Edition
v v v v v v v




MULTIPLEvCHOICE

1. WhichvnamevidentifiesvavdrugvlistedvbyvthevUSvFoodvandv
DrugvAdministrationv(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:vC
Thevofficialvnamevisvthevnamevundervwhichvavdrugvisvlistedvbyv
thevFDA.vThevbrandvname,vorvtrademark,visvthevnamevgivenvto
vavdrugvbyvitsvmanufacturer.vThevnonproprietary, vorvgeneric,vn

amevisvprovidedvbyvthevUnitedvStatesvAdoptedvNamesvCounci
l.

DIF: CognitivevLevel:vKnowledge REF:vp.v9
OBJ:v1NAT:vNCLEXvClientvNeedsvCategory:vSafe,vEffectivevCarev
EnvironmentvTOP:v NursingvProcessvStep:vAssessment
CON:v
PatientvEducation

2. Whichvsourcevcontainsvinformationvspecificvtovnutritionalsupplements?
a. USPvDictionaryvofvUSANv&vInternationalvDrugvNames
b. NaturalvMedicinesvComprehensivevDatabase
c. UnitedvStatesvPharmacopoeia/NationalvFormularyv(USPNF)
d. DrugvInteractionvFacts
ANS:vC
UnitedvStatesvPharmacopoeia/NationalvFormularyvcontainsvinformationvspecificvtovnutritionalvs
upplements.vUSPvDictionaryvofvUSANv&vInternationalvDrugvNamesvisvavcompilationvofvdrugvna
mes,vpronunciationvguide,vandvpossiblevfuturevFDAvapprovedvdrugs;vitvdoesvnotvincludevnutritio
nalvsupplements.vNaturalvMedicinesvComprehensivevDatabasevcontains
evidence-
basedvinformationvonvherbalvmedicinesvandvherbalvcombinationvproducts;vitvdoesvnotvincludevinf
ormationvspecificvtovnutritionalvsupplements.vDrugvInteractionvFactsvcontainsvcomprehensivevi
nformationvonvdrugvinteractionvfacts;vitvdoesvnotvincludevnutritionalvsupplements.

DIF: CognitivevLevel:vKnowledge REF:v p.v4
OBJ:v3vNAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegr
ity
TOP:v NursingvProcessvStep:vAssessment CON:vNutritionv|vPatientvEducation

3. Whichvdrugvreferencevcontainsvdrugvmonographsvthatvdescribevallvdrugsvinvavtherapeuticvclass?
a. DrugvFactsvandvComparisons

, b. DrugvInteractionvFacts
c. HandbookvonvInjectablevDrugs
d. Martindale—ThevCompletevDrugvReference
ANS:vA
DrugvFactsvandvComparisonsvcontainsvdrugvmonographsvthatvdescribevallvdrugsvinvavth
erapeuticvclass.vMonographsvarevformattedvasvtablesvtovallowvcomparisonvofvsimilarvpro
ducts,vbrandvnames,vmanufacturers,vcostvindices,vandvavailablevdosagevformsvOnlinevve
rsionvisvavailable.

DIF: CognitivevLevel:vKnowledge REF:vp.v4vTablev1.2
OBJ:v v 3 NAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegrity
TOP:v NursingvProcessvStep:vAssessment CON:vSafetyv|vPatientvEducationv|vClinicalvJudgment

4. Whichvdrugvreferencevcontainsvmonographsvaboutvvirtuallyveveryvsingle-
entitydrugvavailablevinvthevUnitedvStatesvandvdescribesvtherapeuticvusesvofvdrugs,vincludingvap
provedvandvunapprovedvuses?
a. Martindale:vThevCompletevDrugvReference
b. AHFSvDrugvInformation
c. DrugvReference
d. DrugvFactsvandvComparisons
ANS:vB
AHFSvDrugvInformationvcontainsvmonographsvaboutvvirtuallyveveryvsingle-
entityvdrugvavailablevinvthevUnitedvStatesvandvdescribesvtherapeuticvusesvofvdrugs,vincludingvapp
rovedvandvunapprovedvuses.

DIF: CognitivevLevel:vKnowledge REF:vp.v4vTablev1.2
OBJ:v v 3 NAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegrity
TOP:v NursingvProcessvStep:vPlanning CON:vSafetyv|vPatientvEducationv|vClinicalvJudgment

5. Whichvonlinevdrugvreferencevmakesvavailablevtovhealthcarevprovidersvandvthevpublicvavstand
ard,vcomprehensive,vup-to-datevlookvupvandvdownloadablevresourcevaboutvmedicines?
a. AmericanvDrugvIndex
b. AmericanvHospitalvFormulary
c. DailyMed
d. DrugvReference
ANS:vC
DailyMedvmakesvavailablevtovhealthcarevprovidersvandvthevpublicvavstandard,vcomprehensive,v
up-to-
datevlookvupvandvdownloadablevresourcevaboutvmedicines.vThevAmericanvDrugvIndexvisvnotvapp
ropriatevforvpatientvuse.vThevAmericanvHospitalvFormularyvisvnotvappropriatevforvpatientvuse.vT
hevdrugvreferencevisvnotvappropriatevforvpatientvuse.

DIF: CognitivevLevel:vKnowledge REF:v p.v3v|p.v4
OBJ:v3vNAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegr
ity
TOP:vNursingvProcessvStep:vImplementation
CON:vSafetyv|vPatientvEducationv|vClinicalvJudgment

6. WhichvlegislationvauthorizesvthevFDAvtovdeterminevthevsafetyvofvavdrugvbeforevitsvmarketing?
a. FederalvFood,vDrug,vandvCosmeticvActv(1938)
b. DurhamvHumphreyvAmendmentv(1952)

, c. ControlledvSubstancesvActv(1970)
d. KefauvervHarrisvDrugvAmendmentv(1962)

ANS:vA
ThevFederalvFood,vDrug,vandvCosmeticvActvofv1938vauthorizedvthevFDAvtovdeterminevthevsafety
vofvall vdrugsvbeforevmarketing.vLatervamendmentsvandvactsvhelpedvtightenvFDAvcontrolvandvensu

revdrugvsafety.vThevDurhamvHumphreyvAmendmentvdefinesvthevkindsvofvdrugsvthatvcannotvbevus
edvsafelyvwithoutvmedicalvsupervisionvandvrestrictsvtheirvsalevtovprescriptionvbyvavlicensedvpracti
tioner.vThevControlledvSubstancesvActvaddressesvonlyvcontrolledvsubstancesvandvtheirvcategoriz
ation.vThevKefauvervHarrisvDrugvAmendmentvensuresvdrugvefficacyvandvgreatervdrugvsafety.vDr
ugvmanufacturersvarevrequiredvtovprovevtovthevFDAvtheveffectivenessvofvtheirvproductsvbeforevm
arketingvthem.

DIF: CognitivevLevel:vKnowledge REF:vp.v5vTablevl.3
OBJ:v 5
NAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegrityv
TOP:vNursingvProcessvStep:vAssessment
CON:vSafetyv|vPatientvEducationv|vEvidencev|vHealthvCarevLaw

7. Whichvclassificationvdoesvmeperidinev(Demerol)vfallvunder?
a. I
b. II
c. III
d. IV
ANS:vB
Meperidinev(Demerol)visvavSchedulevIIvdrug;vitvhasvavhighvpotentialvforvabusevandvmayvleadvtovse
verevpsychologicalvandvphysicalvdependence.vSchedulevIvdrugsvhavevhighvpotentialvforvabusevan
dvnovrecognizedvmedicalvuse.vSchedulevIIIvdrugsvhavevsomevpotentialvforvabuse.vUsevmayvleadvt
ovlowvtovmoderatevphysicalvdependencevorvhighvpsychologicalvdependence.vSchedulevIVvdrugsv
havevlowvpotentialvforvabuse.vUsevmayvleadvtovlimitedvphysicalvorvpsychologicalvdependence.

DIF: CognitivevLevel:vKnowledge REF:v p.v10
OBJ:v2vNAT:vNCLEXvClientvNeedsvCategory:vSafe,vEffectivevCare
vEnvironment

TOP:v NursingvProcessvStep:vAssessment CON:vPatientvEducationv|vAddictionv|vPain

8. WhichvactionvwouldvthevFDAvtakevtovexpeditevdrugvdevelopmentvandvapprovalvforvanvoutbreakvo
fvsmallpox?
a. Listvsmallpoxvasvavhealthvorphandisease.
b. Omitvthevpreclinicalvresearchphase.
c. Extendvthevclinicalvresearchvphase.
d. Fastvtrackvthevinvestigationalvdrug.
ANS:vD
OncevthevInvestigationalvNewvDrugvApplicationvhasvbeenvapproved,vthevdrugvcanvreceivevhigh
estvpriorityvwithinvthevagency,vwhichvisvcalledvfastvtracking.vAvsmallpoxvoutbreakvwouldvbeco
mevavpriorityvconcernvinvthevworld.vOrphanvdiseasesvarevnotvresearchedvinvavpriorityvmanner.vPr
eclinicalvresearchvisvnotvomitted.vExtendingvanyvphasevofvthevresearchvwouldvmeanvavlongervtim
evtovdevelopvavvaccine.vThevFDAvmustvensurevthatvallvphasesvofvthevpreclinicalvandvclinicalvresea
rchvphasevhavevbeenvcompletedvinvavsafevmanner.

DIF: CognitivevLevel:vKnowledge REF:v v p.v7 OBJ:v 5

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Verifiedtestbanks. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for CA$30.76. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

55939 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
CA$30.76
  • (0)
Add to cart
Added